GlassScriptPhysician profile
Denise R Dingle
NPI 1518974732
$1,699.87
in general payments reported to CMS, 2019-2025
27 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $165 · 2021: $204 · 2022: $247 · 2023: $220 · 2024: $321 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $318.42 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $265.06 | 2021-2025 | Vraylar |
| Pfizer INC. | $147.26 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.54 | 2025 | Caplyta |
| Novo Nordisk INC | $101.00 | 2020-2023 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $95.57 | 2020-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $82.21 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.42 | 2022-2025 | |
| Astellas Pharma US INC | $60.52 | 2022-2025 | Veozah |
| Cmp Pharma, INC. | $57.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.38 | 2024 | Jardiance |
| Exact Sciences Corporation | $45.15 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $44.26 | 2022-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $41.93 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.66 | 2019-2025 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $23.34 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.43 | 2023 | |
| Lundbeck LLC | $16.81 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $15.59 | 2024 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $14.95 | 2024 | Nuzyra |
| Verona Pharma, INC. | $14.66 | 2025 | Ohtuvayre |
| Avanir Pharmaceuticals, INC. | $13.80 | 2020 | |
| Daiichi Sankyo INC. | $13.74 | 2020 | |
| Insulet Corporation | $12.26 | 2021 | |
| Amgen INC. | $11.76 | 2020 | |
| Eisai INC. | $11.48 | 2020 | |
| Athena Bioscience, LLC | $8.66 | 2024 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Dingle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.